Human gut microbiome: Hopes, threats and promises

Gut

Volumn 67, Issue 9, 2018, Pages 1716-1725

  Cani, Patrice D ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

diabetes mellitus; intestinal microbiology; obesity

Indexed keywords

PROBIOTIC AGENT;

AKKERMANSIA MUCINIPHILA; CANCER IMMUNOTHERAPY; DEGENERATIVE DISEASE; DIET; DISEASE COURSE; ENVIRONMENTAL FACTOR; FECES INCONTINENCE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART DISEASE; HOST CELL; HUMAN; IMMUNITY; INSULIN SENSITIVITY; INTESTINE FLORA; INTESTINE MOTILITY; METABOLIC DISORDER; METAGENOMICS; MICROBIAL ACTIVITY; MICROBIAL METABOLISM; NONHUMAN; ORGANISMAL INTERACTION; PATHOGENESIS; PREVOTELLA; PREVOTELLA COPRI; PRIORITY JOURNAL; PROOF OF CONCEPT; REVIEW; DIABETES MELLITUS; DYSBIOSIS; EVIDENCE BASED MEDICINE; IMMUNOLOGY; LIVER DISEASE; METABOLISM; MICROBIOLOGY; NEOPLASM; OBESITY; VERRUCOMICROBIA;

DIABETES MELLITUS; DYSBIOSIS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER DISEASES; METABOLIC DISEASES; NEOPLASMS; NEURODEGENERATIVE DISEASES; OBESITY; PREVOTELLA; VERRUCOMICROBIA;

EID: 85049137140     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-316723     Document Type: Review

References (132)

1. Chu H, Mazmanian SK. Innate immune recognition of the microbiota promotes hostmicrobial symbiosis. Nat Immunol 2013;14:668-75.
2. Cabinian A, Sinsimer D, Tang M, et al. Gut symbiotic microbes imprint intestinal immune cells with the innate receptor SLAMF4 which contributes to gut immune protection against enteric pathogens. Gut 2017.
3. Sprockett D, Fukami T, Relman DA. Role of priority effects in the early-life assembly of the gut microbiota. Nat Rev Gastroenterol Hepatol 2018;15:197-205.
4. Ximenez C, Torres J. Development of microbiota in infants and its role in maturation of gut mucosa and immune system. Arch Med Res 2017;48:666-80.
5. Milani C, Duranti S, Bottacini F, et al. The first microbial colonizers of the human gut: Composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017.
6. Tilg H, Adolph TE, Gerner RR, et al. The intestinal microbiota in colorectal cancer. Cancer Cell 2018.
7. Bachmann R, Leonard D, Delzenne N, et al. Novel insight into the role of microbiota in colorectal surgery. Gut 2017;66:738-49.
8. Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol 2018;15:382-96.
9. Shanahan F, van Sinderen D, O'Toole PW, et al. Feeding the microbiota: Transducer of nutrient signals for the host. Gut 2017;66:1709-17.
10. Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 2018:gutjnl-2016-313498.
11. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018;67:226-36.
12. Ogino S, Nowak JA, Hamada T, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut 2018;67:1168-80.
13. Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 2017;372:gutjnl-2017-313952.
14. Bakhshinejad B, Ghiasvand S. Bacteriophages in the human gut: Our fellow travelers throughout life and potential biomarkers of heath or disease. Virus Res 2017;240:47-55.
15. Barr JJ. A bacteriophages journey through the human body. Immunol Rev 2017;279:106-22.
16. Forde A, Hill C. Phages of life-the path to pharma. Br J Pharmacol 2018;175:412-8.
17. Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends Microbiol 2014;22:399-405.
18. Shkoporov AN, Ryan FJ, Draper LA, et al. Reproducible protocols for metagenomic analysis of human faecal phageomes. Microbiome 2018;6:68.
19. O'Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol 2013;13:453-60.
20. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol 2014;14:667-85.
21. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010;10:159-69.
22. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72.
23. Everard A, Geurts L, Caesar R, et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 2014;5:5648.
24. Duparc T, Plovier H, Marrachelli VG, et al. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Gut 2017;66:620-32.
25. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87:1219-23.
26. Lassenius MI, Pietilaïnen KH, Kaartinen K, et al. Bacterial endotoxin activity in guman serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011;34:1809-15.
27. Pussinen PJ, Havulinna AS, Lehto M, et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011;34:392-7.
28. Monte SV, Caruana JA, Ghanim H, et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2011.
29. Laugerette F, Vors C, Géloën A, et al. Emulsified lipids increase endotoxemia: Possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011;22:53-9.
30. Radilla-Vázquez RB, Parra-Rojas I, Martínez-Hernández NE, et al. Gut microbiota and metabolic endotoxemia in young obese Mexican subjects. Obes Facts 2016;9:1-11.
31. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism 2017;68:133-44.
32. Gummesson A, Carlsson LMS, Storlien LH, et al. Intestinal permeability is associated with visceral adiposity in healthy women. Obesity 2011;19:2280-2.
33. Jayashree B, Bibin YS, Prabhu D, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 2014;388:203-10.
34. Horton F, Wright J, Smith L, et al. Increased intestinal permeability to oral chromium (51 Cr)-EDTA in human Type 2 diabetes. Diabet Med 2014;31:559-63.
35. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-31.
36. Chassaing B, Ley RE, Gewirtz AT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology 2014;147:1363-77.
37. Denou E, Lolmede K, Garidou L, et al. Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. EMBO Mol Med 2015;7:259-74.
38. König J, Wells J, Cani PD, et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol 2016;7:e196.
39. Wells JM, Brummer RJ, Derrien M, et al. Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol 2017;312:G171-G193.
40. Monteiro-Sepulveda M, Touch S, Mendes-Sá C, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab 2015;22:113-24.
41. Magalhaes I, Pingris K, Poitou C, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 2015;125:1752-62.
42. Husted AS, Trauelsen M, Rudenko O, et al. GPCR-mediated signaling of metabolites. Cell Metab 2017;25:777-96.
43. Pallister T, Jackson MA, Martin TC, et al. Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. Sci Rep 2017;7:13670.
44. Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol 2018;16:171-81.
45. Rastelli M, Knauf C, Cani PD. Gut microbes and health: A focus on the mechanisms linking microbes, obesity, and related disorders. Obesity 2018;26:792-800.
46. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 2015;277:32-48.
47. Kasselman LJ, Vernice NA, DeLeon J, et al. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis 2018;271:203-13.
48. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-9.
49. Kimura I, Inoue D, Hirano K, et al. The SCFA receptor GPR43 and energy metabolism. Front Endocrinol 2014;5:85.
50. McKenzie C, Tan J, Macia L, et al. The nutrition-gut microbiome-physiology axis and allergic diseases. Immunol Rev 2017;278:277-95.
51. Postler TS, Ghosh S. Understanding the holobiont: How microbial metabolites affect human health and shape the immune system. Cell Metab 2017.
52. Brooks L, Viardot A, Tsakmaki A, et al. Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansion to increase satiety. Mol Metab 2017;6:48-60.
53. Cani PD, Everard A, Duparc T, et al. Enteroendocrine functions and metabolism. Curr Opin Pharmacol 2013;13:935-40.
54. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282-6.
55. Sivaprakasam S, Gurav A, Paschall AV, et al. An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. Oncogenesis 2016;5:e238.
56. Bindels LB, Porporato P, Dewulf EM, et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 2012;107:1337-44.
57. Byndloss MX, Olsan EE, Rivera-Chávez F, et al. Microbiota-activated PPAR-signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 2017;357:570-5.
58. Cani PD. Gut cell metabolism shapes the microbiome. Science 2017;357:548-9.
59. Rivera-Chávez F, Lopez CA, Baümler AJ. Oxygen as a driver of gut dysbiosis. Free Radical Biology and Medicine 2017;105:93-101.
60. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-131.
61. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut 2016;65:2035-44.
62. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576-85.
63. Vandeputte D, Kathagen G, D'hoe K, D'Hoe K, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 2017;352:507-11.
64. Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat Microbiol 2018.
65. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013;152:39-50.
66. Franzosa EA, Hsu T, Sirota-Madi A, et al. Sequencing and beyond: Integrating molecular 'omics' for microbial community profiling. Nat Rev Microbiol 2015;13:360-72.
67. Suez J, Elinav E. The path towards microbiome-based metabolite treatment. Nat Microbiol 2017;2:17075.
68. Kashyap PC, Chia N, Nelson H, et al. Microbiome at the frontier of personalized medicine. Mayo Clin Proc 2017;92:1855-64.
69. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-94.
70. Noecker C, Borenstein E. Getting personal about nutrition. Trends Mol Med 2016;22:83-5.
71. Lau JT, Whelan FJ, Herath I, et al. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med 2016;8:72.
72. Browne HP, Forster SC, Anonye BO, et al. Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature 2016;533:543-6.
73. Guilhot E, Khelaifia S, La Scola B, et al. Methods for culturing anaerobes from human specimen. Future Microbiol 2018;13:369-81.
74. De Vadder F, Kovatcheva-Datchary P, Zitoun C, et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab 2016;24:151-7.
75. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014;156:84-96.
76. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016;535:376-81.
77. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004;54:1469-76.
78. Gómez-Gallego C, Pohl S, Salminen S, et al. Akkermansia muciniphila: A novel functional microbe with probiotic properties. Benef Microbes 2016;7:571-84.
79. Cani PD, de Vos WM. Next-generation beneficial microbes: The case of Akkermansia muciniphila. Frontiers in microbiology 1765;2017:8.
80. Mithieux G. Does Akkermansia muciniphila play a role in type 1 diabetes? Gut 2018:gutjnl-2017-315732.
81. Romaní-Pérez M, Agusti A, Sanz Y. Innovation in microbiome-based strategies for promoting metabolic health. Curr Opin Clin Nutr Metab Care 2017;20:1-91.
82. Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011;60:2775-86.
83. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Nat Acad Sci 2013;110:9066-71.
84. Everard A, Lazarevic V, Gaiä N, et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. Isme J 2014;8:2116-30.
85. Ojo B, El-Rassi GD, Payton ME, et al. Mango supplementation modulates gut microbial dysbiosis and short-chain fatty acid production independent of body weight reduction in C57BL/6 mice fed a high-fat diet. J Nutr 2016;146:1483-91.
86. Song H, Chu Q, Yan F, et al. Red pitaya betacyanins protects from diet-induced obesity, liver steatosis and insulin resistance in association with modulation of gut microbiota in mice. J Gastroenterol Hepatol 2016;31:1462-9.
87. Schneeberger M, Everard A, Gómez-Valadés AG, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 2015;5:16643.
88. Singh DP, Singh J, Boparai RK, et al. Isomalto-oligosaccharides, a prebiotic, functionally augment green tea effects against high fat diet-induced metabolic alterations via preventing gut dysbacteriosis in mice. Pharmacol Res 2017;123:103-13.
89. Leal-Diáz AM, Noriega LG, Torre-Villalvazo I, et al. Aguamiel concentrate from Agave salmiana and its extracted saponins attenuated obesity and hepatic steatosis and increased Akkermansia muciniphila in C57BL6 mice. Sci Rep 2016;6:34242.
90. Carmody RN, Gerber GK, Luevano JM, et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 2015;17:72-84.
91. Anhê FF, Roy D, Pilon G, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015;64:872-83.
92. Greer RL, Dong X, Moraes ACF, et al. Akkermansia muciniphila mediates negative effects of IFNon glucose metabolism. Nat Commun 2016;7:13329.
93. Cani PD, Knauf C, Iglesias MA, et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006;55:1484-90.
94. Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013;8:e71108.
95. Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017;5:14.
96. Grander C, Adolph TE, Wieser V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 2017.
97. Yassour M, Lim MY, Yun HS, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med 2016;8:17.
98. Dao MC, Everard A, Aron-Wisnewsky J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut 2016;65:426-36.
99. Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology 2018.
100. Khan TJ, Ahmed YM, Zamzami MA, et al. Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients. OMICS 2018;22:154-63.
101. Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014;63:727-35.
102. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262-6.
103. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 2017;40:54-62.
104. Wang ZS, Horn S; Van, Thomas S;, et al. Gut microbiome differences between metformin-A nd liraglutide-treated T2DM subjects. Endocrinol Diab Metab 2017:e00009.
105. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107-13.
106. Li J, Lin S, Vanhoutte PM, et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/-mice. Circulation 2016;133:2434-46.
107. Hänninen A, Toivonen R, Poÿsti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 2017:gutjnl-2017-314508.
108. Shen J, Tong X, Sud N, et al. Low-density lipoprotein receptor signaling mediates the triglyceride-lowering action of Akkermansia muciniphila in genetic-induced hyperlipidemia. Arterioscler Thromb Vasc Biol 2016;36:1448-56.
109. Ottman N, Reunanen J, Meijerink M, et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One 2017;12:e0173004.
110. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84.
111. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7.
112. Jobin C. Precision medicine using microbiota. Science 2018;359:32-4.
113. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104-8.
114. Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 2017;114:10719-24.
115. Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA 2017;114:10713-8.
116. Heintz-Buschart A, Pandey U, Wicke T, et al. The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord 2018;33:88-98.
117. Hill-Burns EM, Debelius JW, Morton JT, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 2017;32:739-49.
118. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490:55-60.
119. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498:99-103.
120. Reveles KR, Ryan CN, Chan L, et al. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut 2017.
121. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016;65:749-56.
122. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut 2016;65:740-8.
123. Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 2016;65:57-62.
124. Remely M, Hippe B, Geretschlaeger I, et al. Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: A pilot study. Wien Klin Wochenschr 2015;127:394-8.
125. Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell 2014;159:789-99.
126. Udayappan SD, Kovatcheva-Datchary P, Bakker GJ, et al. Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLoS One 2017;12:e0181693.
127. Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. Isme J 2013;7:880-4.
128. Knight R, Callewaert C, Marotz C, et al. The microbiome and human biology. Annu Rev Genomics Hum Genet 2017;18:65-86.
129. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.
130. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017;14.
131. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005;3:431-8.
132. Wolever TMS. Personalized nutrition by prediction of glycaemic responses: Fact or fantasy? Eur J Clin Nutr 2016;70:411-3.